Diabetic neuropathy

Handbook of Peripheral Neuropathy

Volumn , Issue , 2005, Pages 179-204

  Smith, A Gordon ^a   Singleton, J Robinson ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867899728     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (157)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:1183-1199.
2. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1:168.
3. Dyck PJ, Kratz JM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O’Brien PC, Melton LJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993; 43:817-824.
4. The Italian General Practitioner Study Group. Chronic symmetric symptomatic polyneuropathy in the elderly: A field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology 1995; 45:1832-1836.
5. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24:1448-1453.
6. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001; 24:1225-1228.
7. Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001; 24:1229-1231.
8. Sumner C, Seth S, Griffin J, Cornblath D, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60:108-111.
9. Alberti KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998; 40:S3-S8.
10. Dyck JB, Dyck PJ. Diabetic Polyneuropathy. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. Philadelphia: WB Saunders, 1999:255-278.
11. Ellenberg M. Diabetic neuropathy presenting as the initial clinical manifestation of diabetes. Ann Intern Med 1958; 49:620-631.
12. Lehtinen JM, Uuistupa M, Siitonen O, Pyorala K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 1989; 38:1308-1313.
13. Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin dependent diabetes mellitus (NIDDM). Muscle Nerve 1998; 21:72-80.
14. Franklin GM, Kahn LB, Marshall JA, Hamman RF. Sensory neuropathy in non-insulindependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990; 131:633-643.
15. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. J Diab Comp 1992; 6:49-57.
16. Archer A, Watkins PJ, Thomas PK. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psych 1983; 46:491-497.
17. Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG, Ward JD. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996; 39:329-335.
18. Burchiel KJ, Russell LC, Lee RP, Sima AAF. Spontaneous activity of primary afferent neurons in diabetic BB/wistar rats: a possible mechanism of chronic diabetic neuropathic pain. Diabetes 1985; 36:1210-1213.
19. Boulton A. What causes neuropathic pain? J Diab Comp 1992; 6:58-63.
20. Guy RJ, Clark CA, Malcolm PN, Watkins PJ. Evaluation of thermal and vibration sensation in diabetic neuropathy. Diabetologia 1985; 28:131-137.
21. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997; (suppl 2):S54-S57.
22. Brown MJ, Asbury AK. Diabetic neuropathy. Ann Neurol 1984; 15:2-12.
23. Dunsmuir WD, Holmes SA. The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus. Diab Med 1996; 13:700-708.
24. Periquet MI, Novak V, Collins MP, Nagaraja HN, Erdem S, Nash SM, Freimer ML, Sahenk Z, Kissel JT, Mendel JR. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 1999; 53:1641-1647.
25. Holland NR, Crawford TO, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol 1998; 44:47-59.
26. Freeman R, Chase K, Risk M. Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy. Neurology 2003; 60:465-470.
27. Smith AG, Tripp C, Singleton JR. Skin biopsy findings in patients with neuropathy associated with diabetes and impaired glucose tolerance. Neurology 2001; 57:1701.
28. Dyck PJ, Lais A, Karnes JL, O’Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986; 19:425-439.
29. Timperley WR, Boulton AJ, Davies-Jones GA, Jarrett JA, Ward JD. Small vessel disease in progressive diabetic neuropathy associated with good metabolic control. J Clin Pathol 1985; 38:1030-1038.
30. Gianni C, Dyck PJ. Basement membrane thickening and pericyte degeneration precede development of diabetes polyneuropathy and are associated with its severity. Ann Neurol 1995; 37:498-504.
31. Herrmann D, Griffin J, Hauer P, Cornblath DR, McArthur JC. Epidermal nerve fiber density:association with sural nerve morphometry and electrophysiology in peripheral neuropathies. Neurology 1999; 52:A309-A310.
32. Low PA. Diabetic autonomic neuropathy. Sem Neurol 1996; 16:143-151.
33. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26:1553-1579.
34. Deutsch S, Sherman L. Previously unrecognized diabetes mellitus in sexually impotent men. J Am Med Assoc 1980; 244:2430-2432.
35. Sairam K, Kulinskaya E, Boustead GB, Hanbury DC, McNicholas TA. Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int 2001; 88:68-71.
36. Maatman TJ, Montague DK, Martin LM. Erectile dysfunction in men with diabetes mellitus. Urology 1987; 29:589-592.
37. Bemelmans BL, Meuleman EJ, Doesburg WH, Notermans SL, Debruyne FM. Erectile dysfunction in diabetic men: the neurological factor revisited. J Urol 1994; 151:884-889.
38. Benvenuti F, Boncinelli L, Vignoli GC. Male sexual impotence in diabetes mellitus:vasculogenic versus neurogenic factors. Neurourol Urodyn 1993; 12:145-151.
39. Lustman PJ, Clouse RE. Relationship of psychiatric illness to impotence in men with diabetes. Diabetes Care 1990; 13:893-895.
40. Low PA. Autonomic nervous system function. J Clin Neurophys 1993; 10:14-27.
41. American Diabetes Association. Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1993; 16:72-78.
42. Stevens MJ, Feldman EL, Thomas T, Greene DA. Pathogenesis of diabetic neuropathy. In:Veves A, ed. Clinical Management of Diabetic Neuropathy. Totowa: Humana Press, 1998.
43. Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. Arch Intern Med 1990; 150:1218-1222.
44. Orchard T, CE L, Maser R, Kuller L. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract 1996; 34(suppl):S165-S171.
45. Fava S, Azzopardi J, Muscatt HA, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 1993; 16:1615-1618.
46. Schiller LR, Santa Ana CA, Schmulen AC, Hendler RS, Harford WV, Fordtran JS. Pathogenesis of fecal incontinence in diabetes mellitus: evidence for internal-anal-sphincter dysfunction. N Eng J Med 1982; 307:1666-1671.
47. Taborsky GJ, Ahren B, Havel PJ. Autonomic mediation of glucagon secretion during hypoglycemia:implications for impaired alpha-cell responses in type I diabetes. Diabetes 1998; 47:995-1007.
48. Powell AM, Sherwin RS, Shulman GI. Impaired hormonal responses to hypoglycemia in spontaneously diabetic and recurrently hypoglycemic rats. J Clin Invest 1993; 92:2667-2674.
49. Bolli GB, De Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P, Gerich JE. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 1983; 32:134-141.
50. Feldman EL, Stevens MJ, Russell JW, Greene DA. Diabetic neuropathy. In: Taylor S, ed. Current Review of Diabetes. New York, 1999.
51. Cameron N, Eaton S, Cotter M, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44:1973-1988.
52. Dyck P, Hansen S, Karnes J, O’Brien P, Yasuda H, Windebank A. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci 1985; 82:2513-2517.
53. Britland S, Young R, Sharma A, Clarke B. Relationship of endoneurial capillary abnormalities to type and severity of diabetic neuropathy. Diabetes 1990; 39:909-913.
54. Malik R, Newrick PG, Sarma AK, Jennings A, Ah-See AK, Mayhew TM, Jakubowski J, Boulton AJ, Ward JD. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989; 32:92-102.
55. Ibrahim S, Harris N, Radatz M, Selmi F, Rajbhandari S, Brady L, Jakubowski J, Ward JD. A new minimally invasive technique to show nerve ischaemia in diabetic neuropathy. Diabetologia 1999; 36:737-742.
56. Newrick P, Wilson A, Jakubowski J, Boulton A, Ward J. Sural nerve oxygen tension in diabetes. Brit Med J 1986; 293:1053-1054.
57. Reja A, Tesfaye S, Harris N, Ward J. Is ACE inhibition with lisiopril helpful in diabetic neuropathy? Diabetic Med 1995; 12:307-309.
58. Obrosova I, Van Huysen C, Fathallah L, Cao X, Stevens M, Greene D. Evaluation of a1-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioidative defense. FASEB J 2000; 14:1548-1558.
59. Malik R, Williamson S, Abbott C, Carrington A, Iqbal J, Schady W, Boulton A. Effect of the angiotensin converting enzyme inhibitor trandalopril on human diabetic neuropathy: a randomised controlled trial. Lancet 1998; 352:1978-1981.
60. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94:1172-1179.
61. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 2000; 49:684-687.
62. Windebank A, Feldman E. Diabetes and the nervous system. In: Aminoff M, ed. Neurology and General Medicine. Philadelphia, PA: Churchill Livingstone, 2001:341-364.
63. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44:129-146.
64. Cameron N, Cotter M, Achibald V, Dines K, Maxfield E. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin diabetic rats. Diabetologia 1994; 37:449-459.
65. Ward K, Low P, Schmelzer J, Zochodne D. Prostacyclin and moradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain 1989; 112:197-208.
66. Maxfield EK, Cameron NE, Cotter MA. Effects of diabetes on reactivity of sciatic vasa nervorum in rats. J Diabet Complications 1997; 11:47-55.
67. Takahashi K, Ghatei M, Lam H, O’Halloran D, Bloom S. Elevated plasma endothelin levels in patients with diabetes mellitus. Diabetologia 1990; 33:306-310.
68. Suzuki K. Neurological disorders associated with impaired glucose tolerance. Nippon Rinsho 1996; 54:2704-2708.
69. Rezende KF, Melo A, Pousada J, Rezende ZF, Santos NL, Gomes I. Autonomic neuropathy in patients with impaired glucose tolerance. Arq Neuropsiquiatr 1997; 55:703-711.
70. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18:945-959.
71. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999; 104:447-457.
72. King RHM. The role of glycation in the pathogenesis of diabetic polyneuropathy. J Clin Pathol Mol Pathol 2001; 54:400-408.
73. McClain DA, Crook ED. Hexosamines and insulin resistance. Diabetes 1996; 45:1003-1009.
74. Yagihashi S, Yamagishi S, Wada R, Baba M, Hohman T, Yabe-Nishimura C, Kokai Y. Neuropathy in diabetic mice overesxpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001; 124:2448-2458.
75. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46:82-89.
76. Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997; 40:1380-1387.
77. Sima AA, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 1999; 42:773-778.
78. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-820.
79. Pierson CR, Zhang W, Murakawa Y, Sima AA. Early gene responses of trophic factors in nerve regeneration differ in experimental type 1 and type 2 diabetic polyneuropathies. J Neuropathol Exp Neurol 2002; 61:857-871.
80. Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990; 81:402-409.
81. Tomlinson DT, Mayer JH. Defects of axonal transport in diabetes mellitus: a possible contribution to the aetiology of diabetic neuropathy. J Auton Pharmacol 1984; 4:59-68.
82. Migdalis IN, Kalogeropoulou K, Kalantzis L, Nounopoulos C, Bouloukos A, Samartzis M. Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy. Diabet Med 1995; 12:823-827.
83. Delaney CL, Russell JW, Cheng HL, Feldman EL. Insulin-like growth factor-I and overexpression of Bcl-xL prevent glucose-mediated apoptosis in Schwann cells. J Neuropathol Exp Neurol 2001; 60:147-160.
84. Russell JW, Feldman EL. Insulin-like growth factor-I prevents apoptosis in sympathetic neurons exposed to high glucose. Horm Metab Res 1999; 31:90-96.
85. Christianson J, Riekhof J, Wright D. Restorative effects of neurotrophin treatment on diabetes induced cutaneous axon loss in mice. Exp Neurol 2003; 179:188-199.
86. Apfel S, Schwartz S, Adornato B, Freeman J, Biton V, Rendell M, Ninik A, Giuliani M, Stevens J, Barbano R, Dyck P. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy a randomized controlled trial. J Am Med Assoc 2000; 284:2215-2221.
87. Ejskjaer NT, Zanone MM, Peakman M. Autoimmunity in diabetic autonomic neuropathy:does the immune system get on your nerves? Diab Med 1998; 15:723-729.
88. Pittenger GL, Liu D, Vinik AI. The neuronal toxic factor in serum of type 1 diabetic patients is a complement-fixing autoantibody. Diab Med 1995; 12:380-386.
89. Srinivasan S, Stevens MJ, Sheng H, Hall KE, Wiley JW. Serum from patients with type 2 diabetes with neuropathy induces complement-independent, calcium-dependent apoptosis in cultured neuronal cells. J Clin Invest 1998; 102:1454-1462.
90. Ristic H, Srinivasan S, Hall KE, Sima AA, Wiley JW. Serum from diabetic BB/W rats enhances calcium currents in primary sensory neurons. J Neurophys 1998; 80:1236-1244.
91. Stewart JD, McKelvey R, Durcan L, Carpenter S, Karpati G. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci 1996; 142:59-64.
92. Navaro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997; 42:727-736.
93. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial. Ann Neurol 1995; 38:869-880.
94. Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329:977-986.
95. Diabetes Control and Complications Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes 1997; 46:271-286.
96. Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996; 45:1289-1298.
97. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM 2002; 346:393-403.
98. Krentz A, Honigsberger L, Ellis S, Hardman M, Nattrass M. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet Med 1992; 9:463-468.
99. Dyck P, O’Brien P. Meaningful degrees of prevention or improvement of nerve conduction in controlled clnical trials of diabetic neuropathy. Diabetes Care 1989; 12:649-652.
100. Greene D, Arezzo J, Brown M, the Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999; 53:580-591.
101. Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 1995; 44:1355-1361.
102. Dahmen R, Haspels R, Koomen B, Hoeksma AF. Therapeutic footwear for the neuropathic foot: an algorithm. Diabetes Care 2001; 24:705-709.
103. American Diabetes Association. Preventive foot care in people with diabetes. Diab Care 2002; 25(suppl 1):S69-S70.
104. Abbott C, Carrington A, Ashe H, Bath S, Every L, Griffiths J, Hann A, Hussein A, Jackson N, Johnson K, Ryder C, Torkington R, Van Ross E, Whalley A, Widdows P, Williamson S, Boulton A. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19:377-384.
105. Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000; 23:606-611.
106. Perry RC, Baron AD. Impaired glucose tolerance: why is it not a disease? Diabetes Care 1999; 22:883-885.
107. Bonora E, Keichl S, Oberhollenzer, Egger G, Bonadonna RC, Muggeo M, Willeit J. Impaired glucose tolerance, type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia 2000; 42:156-164.
108. Dormandy J, Heeck L, Vig S. Predictors of early disease in the lower limbs. Seminars in Vascular Surgery 1999; 12:109-117.
109. Tominga M, Eguchi H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22:920-924.
110. Tuomilehto J, Del Prato S. Mealtime glucose regulation in type 2 diabetes. Int J Clin Pract 2001; 55:380-383.
111. Garland H. Diabetic myelopathy. Br Med J 1955; 2:1405-1408.
112. Bruns L. Ueber neuritsche Lahmungen beim diabetes mellitus. Berlin Klin Wochenschr 1890; 27:509.
113. Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies:new insights into pathophysiology and treatment. Muscle Nerve 2002; 25:477-491.
114. Dyck P, Norell J, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999; 53:2113-2121.
115. Jaradeh S, Prieto T, Lobeck L. Progressive polyradiculoneuropathy in diabetes: correlation of variables and clinical outcome after immunotherapy. J Neurol Neurosurg Psychiatry 1999; 67:607-612.
116. Katz J, Saperstein D, Wolfe G, Nations S, Alkhersam H, Amato A, Barohn R. Cervicobrachail involvement in diabetic radiculoplexopathy. Muscle Nerve 2001; 24:794-798.
117. Barohn RJ, Sahenk Z, Warmolts J, Mendell J. The Bruns-Garland syndrome (diabetic amyotrophy) revisited 100 years later. Arch Neurol 1991; 48:1130-1135.
118. Bastron J, Thomas J. Diabetic polyradiculopathy clinical and electromyographic findings in 105 patients. Mayo Clin Proc 1981; 56:725-732.
119. Bradley W, Chad D, Verghese J, Liu H, Good P, Gabbai A, Adelman L. Painful lumbosacral plexopathy with elevated erythrocyte sedimentation rate: a treatable inflammatory syndrome. Ann Neurol 1984; 15:725-732.
120. Dyck P, Norell J, Dyck P. Non-diabetic lumbosacral radiculoplexus neuropathy natural history outcome and comparison with the diabetic variety. Brain 2001; 124:1197-1207.
121. Raff M, Asbury A. Ischemic mononeuropathy and mononeuropathy multiplex in diabetes mellitus. N Engl J Med 1968; 279:17-22.
122. Raff M, Sangalang V, Asbury A. Ischemic mononeuropathy multiplex associated with diabetes mellitus. Arch Neurol 1968; 18:487-499.
123. Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994; 35:559-569.
124. Said G, Elgrably F, Lacroix C, Plante V, Talamon C, Adams D, Tager M, Slama G. Painful proximal diabetic neuropathy: inflammatory nerve lesions and spontaneous favorable outcome. Ann Neurol 1997; 41:762-770.
125. Kelkar P, Masood M, Parry G. Distinctive pathologic findings in proximal diabetic neuropathy (diabetic amyotrophy). Neurology 2000; 55:83-88.
126. Llewelyn J, Thomas P, King R. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol 1998; 245:159-165.
127. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995; 52:1053-1061.
128. Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin Proc 1997; 72:1123-1132.
129. Stewart J. Diabetic truncal neuropathy: topography of the sensory deficit. Ann Neurol 1989; 25:233-238.
130. Sun S, Streib E. Diabetic thoracoabdominal neuropathy: clinical and electrodiagnostic features. Ann Neurol 1981; 9:75-79.
131. Waxman S, Sabin T. Diabetic truncal polyneuropathy. Arch Neurol 1981; 38:46-47.
132. Parry G, Floberg J. Diabetic truncal neuropathy presenting as abdominal hernia. Neurology 1989; 39:1488-1490.
133. Lauria G, McArthur J, Hauer P, Griffin J, Cornblath D. Neuropathological alterations in diabetic truncal neuropathy: evaluation by skin biopsy. JNeurolNeurosurg Psychiatry 1998; 65:762-766.
134. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996; 65:39-44.
135. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999; 80:533-538.
136. Richards B, Jones F, Younge B. Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves. Am J Ophthalmol 1992; 113:489-496.
137. Jacobson D. Pupil involvement in patients with diabetes-associated oculomotor palsy. Arch Ophthalmol 1998; 116:723-727.
138. Goldstein J, Cogan D. Diabetic ophthalmoplegia with special reference to the pupil. Arch Ophthalmol 1960; 64:592-600.
139. Rucker C. The causes of paralysis of the third, fourth and sixth cranial nerves. Am J Ophthalmol 1966; 61:1293-1298.
140. Kissel J, Burde R, Klingele T, Zeiger H. Pupil-sparing oculomotor palsies with internal carotid-posterior communicating artery aneurysms. Ann Neurol 1983; 13:149-154.
141. Asbury A, Aldredge H, Hershberg R, Fisher C. Oculomotor palsy in diabetes mellitus: a clinico-pathological study. Brain 1970; 93:555-566.
142. Hopf H, Gutmann L. Diabetic 3rd nerve palsy: evidence for a mesencephalic lesion. Neurology 1990; 40:1041-1045.
143. Aminoff M, Miller A. The prevalence of diabetes in patients with Bell’s palsy. Acta Neurol Scandinav 1972; 48:381-384.
144. Pecket P, Schattner A. Concurrent Bell’s palsy and diabetes mellitus: a diabetic mononeuropathy. J Neurol Neurosurg Psychiatry 1982; 45:652-655.
145. Korczyn A. Bell’s palsy and diabetes mellitus. The Lancet 1971; 1:108-109.
146. Ellenberg M. Diabetic neuropathic cachexia. Diabetes 1974; 23:418-423.
147. D’Costa D, Price D, Burden A. Diabetic neuropathic cachexia associated with malabsorption. Diabet Med 1992; 9:203-205.
148. Jackson CE, Barohn RJ. Diabetic neuropathic cachexia: report of a recurrent case. J Neurol Neurosurg Psychiatry 1998; 64:785-787.
149. Weintrob N, Josefsberg Z, Galazer A, Vardi P, Karp M. Acute painful neuropathic cachexia in a young type 1 diabetic woman. Diabetes Care 1997; 20:290-291.
150. Yuen K, Day J, Flannagan D, Rayman G. Diabetic neuropathic cachexia and acute bilateral cataract formation following rapid glycaemic control in a newly diagnosed type 1 diabetic patient. Diabet Med 2001; 18:854-857.
151. Llewelyn J, Thomas PK, Fonseca V, King RH, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol 1986; 72:157-163.
152. Caravati C. Insulin neuritis: a case report. VA Med Mon 1933; 59:745-746.
153. Patel V, Rassam S, Newsom R, Wiek J, Kohner E. Retinal blood flow in diabetic retinopathy. Br Med J 1992; 305:678-683.
154. Wilbourn AJ. Diabetic entrapment and compression neuropathies. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. Philadelphia: WB Saunders, 1999:481-508.
155. Wilbourn A. Diabetic neuropathies. In: Brown W, Bolton C, eds. Clinical Electromyography. Boston: Butterworth-Heinemann, 1993:477-515.
156. Albers J, Brown M, AA S, Greene D. Frequency of median neuropapthy in patients with mild diabetic neuropathy in the early diabetes intervention trial. Tolrestat Study Group for EDIT (early diabetes intervention trial). Muscle Nerve 1996; 19:140-146.
157. Becker J, Nora D, Gomes I, Stringari F, Seitensus F, Panosso J, Ehlers J. An evaluation of gender, obesity, age and diabetes mellitus as risk factors for carpal tunnel syndrome. Clin Neurophys 2002; 113:1429-1434.